Boston Scientific (BSX)
(Delayed Data from NYSE)
$67.42 USD
-0.54 (-0.79%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $67.42 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Boston Scientific Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 14,240 | 12,682 | 11,888 | 9,913 | 10,735 |
Cost Of Goods | 4,345 | 3,956 | 3,711 | 3,465 | 3,116 |
Gross Profit | 9,895 | 8,726 | 8,177 | 6,448 | 7,619 |
Selling & Adminstrative & Depr. & Amort Expenses | 7,552 | 7,079 | 6,979 | 6,527 | 6,102 |
Income After Depreciation & Amortization | 2,343 | 1,647 | 1,198 | -79 | 1,517 |
Non-Operating Income | -93 | -38 | 218 | 362 | -358 |
Interest Expense | 265 | 470 | 341 | 361 | 473 |
Pretax Income | 1,985 | 1,141 | 1,076 | -79 | 687 |
Income Taxes | 393 | 443 | 36 | 2 | -4,013 |
Minority Interest | 1 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1,592 | 698 | 1,040 | -81 | 4,700 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1,591 | 698 | 1,041 | -82 | 4,700 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 3,597 | 2,915 | 2,661 | 1,577 | 2,633 |
Depreciation & Amortization (Cash Flow) | 1,254 | 1,268 | 1,463 | 1,656 | 1,116 |
Income After Depreciation & Amortization | 2,343 | 1,647 | 1,198 | -79 | 1,517 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1,463.50 | 1,439.70 | 1,433.80 | 1,416.70 | 1,410.60 |
Diluted EPS Before Non-Recurring Items | 2.05 | 1.71 | 1.63 | 0.96 | 1.58 |
Diluted Net EPS (GAAP) | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 |
Fiscal Year end for Boston Scientific Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3,725.00 | 3,527.00 | 3,599.00 | 3,389.00 |
Cost Of Goods | NA | 1,146.00 | 1,101.00 | 1,058.00 | 1,040.00 |
Gross Profit | NA | 2,579.00 | 2,426.00 | 2,541.00 | 2,349.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1,993.00 | 1,734.00 | 2,027.00 | 1,798.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 586.00 | 692.00 | 514.00 | 551.00 |
Non-Operating Income | NA | -14.00 | -18.00 | -18.00 | -43.00 |
Interest Expense | NA | 64.00 | 66.00 | 70.00 | 65.00 |
Pretax Income | NA | 505.00 | 610.00 | 426.00 | 444.00 |
Income Taxes | NA | 1.00 | 105.00 | 156.00 | 131.00 |
Minority Interest | NA | 1.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 504.00 | 505.00 | 270.00 | 313.00 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 503.00 | 504.00 | 270.00 | 314.00 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1,476.90 | 1,475.00 | 1,456.20 | 1,446.00 |
Diluted EPS Before Non-Recurring Items | NA | 0.55 | 0.50 | 0.53 | 0.47 |
Diluted Net EPS (GAAP) | NA | 0.34 | 0.34 | 0.18 | 0.21 |